Sign inJoin waitlistJoin the waitlist

Pavlos Msaouel

Physician · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
2019–Present

Baylor College of Medicine
Chief Resident2026–Present
2023–2026
University of Texas M D Anderson Cancer Center
2015–2018
Internal Medicine
Jacobi Medical Center
2011–2012
Mayo Clinic
2007–2009
from University of Athens School of Medicine
2002–2006

Research

The role of the insulin-like growth factor-1 system in breast cancer
Review · Molecular Cancer · 2015 · 298 citations
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Nature Medicine · 2020 · 269 citations
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
The Lancet Oncology · 2021 · 154 citations

Nizar Tannir
79 papers
Matthew Campbell
40 papers
Amishi Shah
38 papers · 1 as a fellow
Alex Sherry
37 papers · 37 as a resident
Ethan Ludmir
35 papers
Jianjun Gao
35 papers
Eric Jonasch
31 papers
Jose Karam
26 papers
Omar Alhalabi
26 papers · 6 as a fellow
Priya Rao
25 papers
Ramez Kouzy
25 papers · 25 as a resident
Tim Lin
25 papers · 21 as a resident

Grants

Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation
National Cancer Institute · R01
PI · $2M · University of Tx Md Anderson Can Ctr
2024–2029
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
National Cancer Institute · R37
Contact PI · $2M · University of Tx Md Anderson Can Ctr
2024–2029

Clinical trials

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2030
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2030
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2028
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2027